SGT 501
Alternative Names: SGT-501Latest Information Update: 22 Apr 2024
At a glance
- Originator Solid Biosciences
- Class Antiarrhythmics; Gene therapies
- Mechanism of Action CASQ2 protein replacements; Gene transference; Ryanodine receptor calcium release channel replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Polymorphic catecholergic ventricular tachycardia